Read more
In this study we observed efficacy and safety parameters in both CS and PTZ group. Statistical analysis showed that both the groups were equally effective and safe as an empirical antibiotic therapy for infection in CKD patients and there is no significant difference. CS may be an appropriate choice in case of dosing frequency as it has twice daily dosing. For patients with elevated liver enzymes CS maybe an appropriate choice. Patient with blood disorder or increased prothrombin time PTZ is an appropriate choice. When addressing dose adjustment, PTZ group had more inappropriate dosing according to the Sanford guidelines. Dosing adjustment must be taken in consideration while dosing PTZ for patient with impaired kidney function or reduced creatinine clearance. Prospective multi- centered studies are further needed to evaluate the efficacy and safety of CS and PTZ in CKD patients. Thus, our study concludes CS is as effective as PTZ and safe in CKD patients with infection.
About the author
Dr. Geetha P.Abteilung für pharmazeutische Praxis, Fakultät für Pharmazie,Dr. M.G.R. Bildungs- und Forschungsinstitut(gilt als Universität), Chennai.
